CareDx, Inc. - Common Stock (CDNA)
Frequently Asked Questions About CareDx, Inc. - Common Stock (CDNA)
Does CareDx have any partnerships?
Yes, CareDx has established partnerships with various academic institutions, healthcare providers, and organizations in the transplant community. These collaborations aim to foster research, enhance diagnostic capabilities, and improve overall patient care, helping to drive innovation in transplant medicine.
How can patients access CareDx's services?
Patients can access CareDx's services through their healthcare providers or transplant centers that offer the company's diagnostic tests. Clinicians can order these tests to facilitate patient monitoring and management, ensuring that transplant recipients receive timely and effective care.
How does CareDx contribute to the transplant community?
CareDx contributes to the transplant community by providing innovative diagnostic solutions that enhance patient care, conducting educational initiatives, and engaging in partnerships that promote research and awareness in transplant medicine. The company continually advocates for better health outcomes for transplant patients and supports the healthcare providers involved in their care.
How does CareDx ensure the quality of its products?
CareDx ensures the quality of its products through rigorous testing, adherence to regulatory standards, and continuous quality improvement practices. The company is committed to maintaining high-quality diagnostic standards that meet the expectations of healthcare providers and regulatory agencies.
How does CareDx support transplant patients?
CareDx supports transplant patients through its innovative diagnostics, such as AlloSure and AlloMap, alongside patient-centered solutions. These tools allow for continuous monitoring of transplant health, which is crucial for timely intervention and improving long-term outcomes in organ transplantation.
How many employees does CareDx have?
As of the latest reports, CareDx employs a team of approximately 200 professionals. The workforce includes a diverse range of experts in biotechnology, diagnostics, research, and customer support, all working together to drive the company’s mission forward.
Is CareDx publicly traded?
Yes, CareDx, Inc. is publicly traded on the Nasdaq stock exchange under the ticker symbol CDNA. The company went public in 2014 and has since been committed to advancing transplant health through its innovative products and services.
What are CareDx's future plans?
CareDx aims to expand its portfolio of transplant diagnostic solutions, invest in research and development, and enhance its existing services. The company is focused on addressing unmet needs in the transplant community and increasing awareness of its products in the medical field to better serve patients.
What are CareDx's main products?
CareDx's main products include AlloSure and AlloMap, both of which are designed to monitor transplant health. AlloSure provides insight into the presence of organ rejection through cell-free DNA analysis, while AlloMap assesses the risk of heart transplant rejection via gene expression profiling.
What are the company's core values?
CareDx's core values center around patient-centric care, innovation, integrity, and collaboration. The company prioritizes the needs of transplant patients and continuously strives to develop better diagnostic tools and services that enhance patient lives and promote positive health outcomes.
What does CareDx, Inc. do?
CareDx, Inc. is a biotechnology company that focuses on providing innovative solutions for transplant patients. The company specializes in transplant diagnostics and monitoring, particularly for kidney, heart, and lung transplants. Their services include genetic testing and cell-free DNA testing, which help clinicians monitor organ transplant health and improve patient outcomes.
What is AlloMap?
AlloMap is a gene expression profiling test offered by CareDx that helps assess the risk of heart transplant rejection. The test analyzes gene activity in a patient's blood sample to provide clinicians with data that aids in the management of heart transplant recipients, thus enhancing patient care.
What is AlloSure?
AlloSure is a non-invasive diagnostic test developed by CareDx that analyzes donor-derived cell-free DNA in the blood of transplant recipients. This test helps physicians assess the health of the transplanted organ, detect potential rejection early, and make informed decisions about patient management.
What is the role of research and development at CareDx?
Research and Development (R&D) at CareDx plays a critical role in the company's growth and innovation. The R&D team is dedicated to discovering and developing new diagnostic tests and technologies that can improve the monitoring and management of organ transplant patients, ultimately contributing to better health outcomes.
What is the significance of CareDx's proprietary technology?
CareDx's proprietary technologies, including its non-invasive tests such as AlloSure and AlloMap, are significant as they provide critical data needed by clinicians to monitor organ transplant health without relying on more invasive procedures like biopsies. This innovation improves patient experience and outcomes.
What markets does CareDx operate in?
CareDx operates primarily in the transplant diagnostics market, focusing on kidney, heart, and lung transplants. The company serves hospitals, transplant centers, and healthcare providers, helping them to better diagnose and monitor the health of transplant recipients.
When was CareDx, Inc. founded?
CareDx, Inc. was founded in 1998. Since its inception, the company has evolved to specialize in transplant diagnostics and has developed innovative products and services aimed at improving patient care for transplant recipients.
Where is the headquarters of CareDx, Inc. located?
The headquarters of CareDx, Inc. is located in Brisbane, California. This strategically positioned location allows the company to be close to key biotech hubs and institutions that are pivotal to the development of their innovative transplant diagnostic solutions.
Who are CareDx's primary competitors?
CareDx competes with other biotechnology companies focused on transplant diagnostics, such as Natera, Inc., and Genomic Health. These companies also develop tests for organ transplant monitoring and genetic analysis, contributing to the overall advancement of the transplant healthcare field.
What is the current price of CareDx, Inc. - Common Stock?
The current price of CareDx, Inc. - Common Stock is 18.39
When was CareDx, Inc. - Common Stock last traded?
The last trade of CareDx, Inc. - Common Stock was at 4:00 pm EDT on April 2nd, 2025
What is the market capitalization of CareDx, Inc. - Common Stock?
The market capitalization of CareDx, Inc. - Common Stock is 967.81M
How many shares of CareDx, Inc. - Common Stock are outstanding?
CareDx, Inc. - Common Stock has 52.63M shares outstanding.